Antibiotics Rewire the Immune Signals of Vaginal Bacteria, Study Finds

Antibiotics are the standard weapon against bacterial vaginosis, one of the most common vaginal conditions in reproductive-age women, yet treatment fails surprisingly often, with symptoms returning in a large share of patients within months. A new study published in the journal Microbiome suggests a reason that has nothing to do with whether the drugs kill bacteria directly. Researchers report that exposure to antibiotics, even at concentrations far below the doses normally considered lethal to microbes, fundamentally changes the inflammatory character of the tiny vesicles that vaginal bacteria release into their surroundings, potentially turning ordinary microbial communication into a trigger for damaging inflammation.

The investigation, led by Yu Hasegawa of the Women’s Biomedical Research Institute at the Icahn School of Medicine at Mount Sinai, together with colleagues at the University of Maryland School of Medicine and other institutions, focused on bacterial extracellular vesicles, or bEVs. These are nanoscale, membrane-bound packages that bacteria shed continuously, carrying proteins, toxins, DNA, RNA, and fragments of cell-wall components. Far from being inert debris, bEVs act as messengers: they travel through the mucus and fluid lining the vaginal tract, dock onto epithelial and immune cells, and deliver molecular signals that can calm or inflame the host. In effect, they form a communication network layered on top of the microbiome itself, and it is this network that the new work shows is scrambled by antibiotic exposure.

The team worked with three species that define very different vaginal states. Lactobacillus crispatus dominates a healthy vaginal microbiome, classified as Community State Type I, and its presence is associated with low inflammation and protection against infection. By contrast, microbiomes dominated by anaerobes such as Gardnerella vaginalis and Mobiluncus mulieris, known as Community State Type IV, are linked to bacterial vaginosis and to serious downstream consequences, including increased susceptibility to sexually transmitted infections, infertility, and preterm birth. Understanding how these species signal to host tissue, and how treatment alters that signaling, is therefore central to explaining why bacterial vaginosis so often recurs after antibiotic therapy.

To probe this, the researchers grew each species in the laboratory and exposed cultures to three clinically relevant antibiotics, ampicillin, clindamycin, and metronidazole, at doses below the minimum inhibitory concentration, the threshold normally required to stop bacterial growth. This sub-minimal dosing was deliberate: in a real vaginal environment, antibiotic concentrations vary widely across time and space, and bacteria in protected niches frequently experience levels that stress rather than kill them. The team then isolated the vesicles released by treated and untreated cultures and quantified them using nanoparticle tracking analysis, a laser-based technique that counts and sizes individual nanoparticles in suspension.

The isolated vesicles were next applied to laboratory cultures of human epithelial and immune cells, and the inflammatory response was measured with cytokine profiling using multiplex immunoassays, which can quantify dozens of immune signaling molecules simultaneously. The researchers also performed Toll-like receptor pathway analyses. Toll-like receptors are pattern-recognition molecules on the surface of host cells that detect conserved microbial structures such as lipoproteins and flagellin, and they sit at the front line of innate immunity, deciding whether a bacterial signal is interpreted as benign or threatening.

The results were striking and highly specific. Antibiotic exposure significantly enhanced the inflammatory properties of the vesicles, but the effect depended on both the bacterial species and the antibiotic involved. Vesicles from antibiotic-exposed Gardnerella vaginalis cultures provoked elevated cytokine responses in host cells primarily through activation of TLR2, the receptor that recognizes bacterial lipoproteins. Vesicles from Mobiluncus mulieris, meanwhile, stimulated inflammation through both TLR2 and TLR5, the latter being the receptor dedicated to detecting flagellin, the protein that builds bacterial tails. These findings indicate that the drugs do not merely reduce bacterial numbers; they change the molecular cargo and immune visibility of the vesicles the surviving bacteria release.

Perhaps the most unexpected result concerned Lactobacillus crispatus. Vesicles from this beneficial species are typically non-inflammatory, consistent with its role in maintaining a calm vaginal environment. Yet when the cultures were exposed to metronidazole, the workhorse drug for bacterial vaginosis, even at a dose lower than what is used clinically, the resulting vesicles became immunostimulatory. In other words, a treatment intended to restore vaginal health may inadvertently push its most protective resident into producing inflammatory signals, an unintended proinflammatory consequence that could help explain why some patients feel worse before they feel better, and why the microbial ecosystem sometimes fails to settle back into a healthy state after therapy.

The study did not stop at laboratory cultures. Examining human vaginal swabs, the researchers detected bacterial extracellular vesicles directly in patient samples, including vesicles carrying vaginolysin, a toxin characteristic of Gardnerella. Notably, such vesicles were found even in swabs from women whose microbiomes were classified as Community State Type I, dominated by Lactobacillus. This indicates that low-abundance microbes, including potential pathogens, remain transcriptionally active even when they are too scarce to register in standard microbiome profiling, quietly releasing vesicles that continue to shape the local immune environment. The vesicle layer, in other words, preserves a memory of the microbial community that simple bacterial census methods miss.

Taken together, the findings suggest that antibiotics reshape bacterial communication in the vagina through their vesicles, potentially contributing to inflammation, disruption of the epithelial barrier that protects underlying tissue, persistent dysbiosis, and the recurrent infections that plague bacterial vaginosis patients. The authors argue that the work underscores the need for precision antimicrobial strategies that eliminate pathogens while preserving beneficial bacteria and their functional vesicles. Future therapies, they suggest, should account for the ecosystem-wide effects of antibiotics on the vaginal microbiome and on the vesicle-mediated signaling network that connects microbes to host immunity. Given the high recurrence rates of bacterial vaginosis and its links to preterm birth and infection risk, treating the vaginal microbiome as an ecosystem to be managed, rather than a pathogen to be eradicated, may prove a decisive shift in women’s health.

Subject of Research: Antibiotic-driven changes in the immune profiles of bacterial extracellular vesicles from vaginal anaerobes

Article Title: Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes

Article References: Hasegawa, Y., Swain, O., Rajpal, U., France, M., Ncube, L., Mogno, I., Zierden, H., Ravel, J., & Elovitz, M. A. (2026). Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes. Microbiome. https://doi.org/10.1186/s40168-026-02510-w

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02510-w

Keywords: vaginal microbiome, bacterial extracellular vesicles, bacterial vaginosis, Gardnerella vaginalis, Lactobacillus crispatus, Mobiluncus mulieris, metronidazole, clindamycin, Toll-like receptors, inflammation, dysbiosis, preterm birth